acute hepatitis C virus infection

Summary

acute hepatitis C virus infection (MONDO:0100371) is a disease and 10 clinical trials. Top therapeutic interventions include grazoprevir anhydrous, elbasvir, and peginterferon alfa-2a. A subtype of hepatitis C virus infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute hepatitis C virus infection
Mondo ID	MONDO:0100371
ICD-10-CM	B17.1
ICD-11	1517862018
NCIT	C157782
Is cancer (heuristic)	no

Also known as: acute hepatitis C

Disease family

This is a subtype of hepatitis C virus infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › hepatitis › viral hepatitis › hepatitis C virus infection › acute hepatitis C virus infection

Related subtypes (1): chronic hepatitis C virus infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	3
PHASE4	2
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01336010	PHASE4	COMPLETED	Treatment of Recently Acquired Hepatitis C Virus Infection
NCT02377856	PHASE4	COMPLETED	Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection
NCT00755950	PHASE2/PHASE3	TERMINATED	Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
NCT02600325	PHASE3	COMPLETED	Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV
NCT02309918	PHASE2	COMPLETED	HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection
NCT02886624	PHASE2	COMPLETED	Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
NCT03818308	PHASE2	COMPLETED	Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
NCT00959166	Not specified	COMPLETED	To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
NCT01289652	Not specified	UNKNOWN	The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals
NCT02000063	Not specified	COMPLETED	Australian Trial in Acute Hepatitis C Recall Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GRAZOPREVIR ANHYDROUS	4	4
ELBASVIR	4	2
PEGINTERFERON ALFA-2A	4	2
RIBAVIRIN	4	2
VELPATASVIR	4	1
LACTOSE MONOHYDRATE	3	1
SILIBININ	3	1
SILYBIN A	3	1
CHEMBL4103158	0	2
CHEMBL4203709	0	2
CHEMBL4472915	0	2
CHEMBL5308485	0	1
SILYBIN B	0	1
SILYMARIN	0	1